Investor Presentaiton
•
•
Key operational highlights (2/2)
* eurofins
Alongside the Core Business, the Group remains equally agile, committed and innovative to fight the pandemic
Significant contribution from COVID-19 related activities and important milestones reached in H1 2021:
Revenue contribution close to EUR 750m
O
O
25+ million COVID-19 PCR tests completed since the start of the pandemic
•
○
125,000+ SARS-CoV-2 samples sequenced from 23 countries since our press release on 28 December 2020
о Broad network of 1,000+ testing centres developed in Europe to facilitate travelling through SAFER@WORK™
Continued progress made in H1 on the completion of Eurofins' infrastructure and operational excellence programmes, to develop an unrivalled,
fully digital network of state-of-the-art laboratories
M&A activity:
O
Very modest level of acquisitions in 2019, 2020 and H1 2021, confirming they are not short-term organic growth drivers
12 acquisitions closed in H1 2021 (EUR 37m full-year equivalent proforma revenues in 2020)
○
○ EUR 225m committed to date in H2 on 7 acquisitions (EUR 95m full-year equivalent proforma revenues in 2020)
O
DNA Diagnostics Center, a leader in consumer genetic testing in the U.S., acquired in July 2021, anticipates delivering revenues of USD
55m+ in 2021
O
On track to achieve objective of adding EUR 150m proforma revenues from M&A in 2021
5View entire presentation